FDA Approves New Option for Small-Cell Lung Cancer

(MedPage Today) -- WASHINGTON--The FDA granted accelerated approval for the transcription inhibitor lurbinectedin (Zepzelca) as second-line therapy for metastatic small-cell lung cancer.
The approval pertains to patients whose disease progressed...